Evidence map›Paper›PMID 39605477›Full record

ArticlebioRxiv : the preprint server for biology2024

Targeted intracellular delivery of molecular cargo to hypoxic human breast cancer stem cells.

Ashley V Makela, Anthony Tundo, Huiping Liu, Doug Schneider, Terry Hermiston, Pavlo Khodakivskyi, Elena Goun, Christopher H Contag

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Ashley V MakelaInstitute for Quantitative Health Science and Engineering, Michigan State University, East Lansing MI.ORCID 0000-0002-2048-6832
Anthony TundoInstitute for Quantitative Health Science and Engineering, Michigan State University, East Lansing MI.
Huiping LiuDepartment of Pharmacology and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
Doug SchneiderGLAdiator BioSciences, Mill Valley, CA.
Terry HermistonGLAdiator BioSciences, Mill Valley, CA.
Pavlo KhodakivskyiDepartment of Chemistry, University of Missouri, Columbia, MO.
Elena GounDepartment of Chemistry, University of Missouri, Columbia, MO.
Christopher H ContagInstitute for Quantitative Health Science and Engineering, Michigan State University, East Lansing MI.ORCID 0000-0002-1011-8278

Funding

Molecular mechanisms underlying circulating tumor cell aggregationR01CA245699 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LIU, HUIPING · 2020 to 2024
$2.0M
NCI NIH HHS R01 CA245699
6 · The paper itself

Abstract

Cancer stem cells (CSCs) drive tumorigenesis, are responsible for metastasis, and resist conventional therapies thus posing significant treatment challenges. CSCs reside in hypoxic tumor regions and therefore, effective therapies must target CSCs within this specific microenvironment. CSCs are characterized by limited distinguishable features, however, surface displayed phosphatidylserine (PS) appears to be characteristic of stem cells and offers a potential target. GlaS, a truncated coagulation protein that is internalized after binding PS, was investigated for intracellular delivery of molecular payloads to CSCs. Intracellular delivery via GlaS was enhanced in patient-derived CD44+ mammary CSCs under hypoxic conditions relative to physoxia or hyperoxia.

Indexed as

cancer stem cellshypoxiapatient derived xenograftphosphatidylserineprotein S

Identifiers

PMID39605477
PMCPMC11601403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.